Christopher Gibson sold $165k of RXRX
Chief Executive Officer at RECURSION PHARMACEUTICALS, INC.. 40,000 shares at an average of $4.12, traded Feb 4, 2026, filed Feb 6, 2026.
Score components
- +15RoleDirector
- +11Trade size$165k at market
- 0Share of holdings soldSold 4.2% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -13.1%, 3m -16.6%, 6m -19.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001601830-26-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 4, 2026 | CConversion Class A Common Stock10b5-1 | +40,000 | $0.00 | $0 | 953,839 | Feb 6, 2026 |
| Feb 4, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -40,000 | $4.12 | $165k | 913,839 | Feb 6, 2026 |
| Feb 6, 2026 | AGrant or award Class A Common Stock10b5-1 | +30,346 | $0.00 | $0 | 944,185 | Feb 6, 2026 |
| Feb 6, 2026 | FTax withholding Class A Common Stock10b5-1 | -10,364 | $3.56 | $37k | 933,821 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Class B Common Stockderivative10b5-1 | -40,000 | $0.00 | $0 | 4,583,334 | Feb 6, 2026 |
Related signals
Other insiders at RECURSION PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 16Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $242k 50,000 shares | -1% | |
| 3Weak | RECURSION PHARMACEUTICALS, INC. | Robert Hershberg director | $125k 25,000 shares | -13% | |
| 22Weak | RECURSION PHARMACEUTICALS, INC. | Najat Khan CEO and President | $79k 22,408 shares | -1% | |
| 13Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $100k 30,000 shares | -0% | |
| 5Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $98k 30,000 shares | -0% | |
| 6Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $159k 40,000 shares | -1% | |
| 10Weak | RECURSION PHARMACEUTICALS, INC. | Namandje Bumpus director | $13k 3,963 shares | -3% | |
| 21Weak | RECURSION PHARMACEUTICALS, INC. | Christopher Gibson Chief Executive Officer | $145k 40,000 shares | -4% | |
| 29Weak | RECURSION PHARMACEUTICALS, INC. | Najat Khan CEO and President | $84k 23,588 shares | -1% | |
| 20Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $110k 30,000 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.